Patients must have previously received at least one line of therapy for their advanced lung cancer; there are no restrictions on the maximum number of prior therapies allowed
No limit on number of prior therapies
Participants are permitted to have any number of prior therapies prior to enrollment
Chemotherapy within  weeks of initiating study treatment; there is no maximum allowable number of previous therapies
Any number of prior chemotherapies and targeted therapies are allowed
Any number of prior systemic therapies.
Participants with prior Hepatitis B or C are eligible on the condition that participants have adequate liver function as defined by Inclusion Criterion number  and Exclusion Criterion number 
Participants may have received any number of prior therapies, from  to > ; prior treatment with phosphatidylinositol  (PI)-kinase or mTOR inhibitors is not permitted, unless they were given as adjuvant therapy without undue toxicity, and without suggestion of resistance to therapy
At least one line of prior systemic therapy for metastatic or recurrent breast cancer (there is no limit to the number of prior therapies)
No limit to number of prior therapies
There is no limit to number of prior therapies
PHASE I: No limit on the number of prior systemic therapies for metastatic disease
There is no limit on the number of prior therapies
Must have received first line chemotherapy; no upper limit to number of prior therapies
Any number of prior therapies are allowed
Have received any number of prior systemic therapies for metastatic disease; prior radiation therapy (any number) and interferon use (any formulation and/or duration) in the adjuvant or metastatic disease settings is permitted; vaccine therapy will be counted as systemic therapy
Patients can have any number of prior therapies and any amount of time period from the last therapy as long as they have complete response as seen in PET/CT at the time of enrolment
Any number of prior treatments allowed for patients under  years (y), over y must have at least one prior line of TKI treatment (excluding anaplastic patients).
Any number of prior therapies is allowed
Patients may have received an unlimited number of prior therapies
Relapse following first line immunotherapy or chemoimmunotherapy; there is no upper limit to the number of therapies received prior to study entry; prior therapies may include high-dose therapy with autologous stem cell rescue
Patients may or may not have received prior therapy for their recurrent/metastatic disease\r\n* NOTE: There is no limit to the number of prior therapies for stage IV disease\r\n* NOTE: Patients should not be a candidate for curative surgical treatment or radiation (palliative radiotherapy is permitted)
There is no limit on number of prior therapies
The number of prior therapies is restricted as follows:\r\n* Zero or one prior therapies during the preceding one year; this serves to limit the treatment cohort to patients with either only slowly progressive disease, or up to one prior therapy\r\n* No prior PD- or PD-L antibody therapies are allowed\r\n* Prior IL- is allowed, if it finished more than  year prior
Any prior number of prior therapies, including prior immunotherapy, is allowed
Metastatic renal cell cancer patients (any histologic subtype) with measurable and/or evaluable disease who have completed at least one line of prior systemic therapy are potentially eligible for this trial; any number of prior systemic therapies are allowed, including prior nivolumab
Patients may be treatment naive or have received any number of prior therapies\r\n* NOTE: Prior immunotherapy is contraindicated and not permitted
Any number of prior therapies as long as patients have adequate performance status and meet all other eligibility criteria
Any number of prior therapies as long as patients have adequate performance status and meet all other eligibility criteria
There is no limit to the number of prior treatments for this phase I trial
No limit in the number of previous surgical resections
Patients may have had any number of prior systemic therapies; patients need not have exhausted standard therapy for their disease, but must be stable and must not have actively progressing
Any number of prior therapies is allowed
Relapsed and/or refractory AML from any duration of complete remission (CR); any number of prior therapies allowed
Any number of prior endocrine therapies is allowed and must be discontinued prior to randomization
Any number of biologic therapies (e.g., bevacizumab) or immunotherapies is allowed in the absence of co-administered chemotherapy and must have been completed >=  days prior to randomization
There is no limit to number of prior therapies
There is no limit to the number of prior chemotherapies
There is no limit to the number of prior therapies
Any number of prior systemic therapies for metastatic/recurrent disease are permitted in both the phase I and II portions of the study; patients need not have received a prior cetuximab-based chemotherapy regimen to be eligible for this trial
Any number of prior therapies (ie, chemotherapy and/or ROS inhibitor therapies).
Participants in Stage  (Safety Evaluation) receiving erlotinib: No limit to the number of prior therapies (except for EGFR TKIs).
Any number of prior therapies is allowed
Participants must have received no more than  prior chemotherapy or cytotoxic regimens; there is no limit to the number of prior hormonal therapies
Any number of prior therapies other than oxaliplatin is allowed
Participants are permitted to have any number of prior therapies prior to enrollment
At least  prior treatment (no restriction to number of prior therapies)
Participants may have received any number of prior therapies as long as they have adequate performance status and meet all other eligibility criteria
Patients may have received any number of prior CNS directed therapies - there are no limitations
Patients must have received at least one prior line of therapy for their advanced lung cancer but there is no restrictions on the maximum number of prior therapies allowed
Prior treatment with embolization of ablative therapies is allowed if measurable disease remains outside of the treated area or if there is definite progression of the treated lesions; there is no limit on the number of prior procedures
Must have received first line chemotherapy; no upper limit for the number of prior therapies
Participants may have received up to  prior cytotoxic chemotherapies; there is no limit to the number of lines of prior biologic or hormonal therapies they may have had; patients must be platinum resistant
Participants may have received any number of prior cytotoxic chemotherapies; there is no limit to the number of lines of prior biologic or hormonal therapies they may have had; patients may be platinum-sensitive or resistant or refractory
Phase Ib: Patients may have had any number of prior treatments, including , or prior pazopanib
For Arm C, patients may have had an unlimited number of prior therapies for GBM, however must be at first recurrence from a therapeutic regimen containing bevacizumab
Patients may have received any number of prior therapies, including monotherapy with liposomal doxorubicin or bevacizumab
At least three weeks from any non-anti-EGFR therapy prior to start of study treatment; any number of prior therapies is permitted
Prior treatment with any number of immunotherapies (e.g., IL, ipilimumab), targeted therapies (e.g., vemurafenib) are permitted but no more than one  prior chemotherapy
For Phase Ib, there is no restriction on the number of prior therapies for recurrent or metastatic disease
Adequate residual organ function per treating physician discretion; Note: there is no limit with regard to the number of prior therapies
No limit on number of prior therapies
Any number of prior therapies are allowed
The number of participants from the same street address will be limited to 
There is no limit to the number of prior therapies
